Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals (EGRX) is a fully integrated specialty pharmaceutical company advancing therapies in oncology, central nervous system disorders, and pediatric critical care. This page serves as the definitive source for official company announcements, clinical trial updates, and regulatory developments.
Investors and healthcare professionals will find curated press releases detailing FDA submissions, partnership agreements, and research breakthroughs. Our repository includes updates on product approvals, manufacturing advancements, and strategic initiatives across EGRX's therapeutic portfolio.
Key content categories include quarterly financial results, clinical study outcomes, intellectual property milestones, and market expansion efforts. All materials are sourced directly from company filings and verified announcements to ensure reliability.
Bookmark this page for streamlined access to EGRX's latest developments. For comprehensive tracking of the company's progress in addressing complex medical needs through innovative pharmaceuticals, we recommend checking back regularly.
Eagle Pharmaceuticals (Nasdaq: EGRX) received a delisting notification from Nasdaq on August 21, 2024, due to its failure to timely file the Q2 2024 Form 10-Q. This follows a previous notice on August 1, 2024, where Nasdaq granted the company continued listing subject to specific conditions. Eagle must file its 2023 Annual Report by September 30, 2024, and both Q1 and Q2 2024 Form 10-Qs by October 31, 2024. The company plans to file a comprehensive Form 10-K, including restated financial information, and separate Form 10-Q filings to meet these deadlines. However, there's no guarantee that Eagle will meet the compliance dates or maintain its Nasdaq listing.
Eagle Pharmaceuticals received a delisting notification from Nasdaq on May 20, 2024, due to its failure to file key financial forms, including the Q3 2023 Form 10-Q, the 2023 Form 10-K, and the Q1 2024 Form 10-Q. The delisting process will commence if Eagle does not request a hearing by May 28, 2024, which will result in the suspension of their stock trading on May 30, 2024. Eagle plans to request a hearing to potentially extend their compliance period. However, there is no guarantee that such an extension will be granted or that they will regain compliance.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced a Trial in Progress presentation for their ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting in pediatric patients at the SAMBA 2024 Annual Meeting. Preliminary results are expected in the first half of 2025. The study aims to evaluate the potential benefits of amisulpride therapy in pediatric patients.
FAQ
What is the current stock price of Eagle Pharmaceut (EGRX)?
What is the market cap of Eagle Pharmaceut (EGRX)?
